胸腺肽α-1辅助治疗哮喘-慢阻肺重叠综合征的治疗效果

Efficacy of Thymosin α-1 Adjuvant Treatment on Asthma-Treatment on COPD Overlap Syndrome

观察胸腺肽α-1辅助治疗哮喘-慢阻肺重叠综合征的治疗效果。收集2012年10月到2013年10月收治住院的84例哮喘-慢阻肺重叠综合征患者,根据是否sc胸腺肽α-1,分为观察组和对照组。考察两组患者在治疗前和治疗4 w后血清T淋巴细胞亚群和肺功能的变化。与治疗前相比,观察组在治疗4 w后血清CD3+、CD4+、CD8+和CD4+/CD8+水平均显著升高(P<0.05);治疗4 w后,与对照组相比,观察组血清CD3+、CD4+、CD8+和CD4+/CD8+水平均发生显著改变(P<0.05);与治疗前相比,观察组和对照组在治疗4 w后FEV1、FEV1/FVC均显著升高(P<0.05);治疗4 w后,与对照组相比,观察组FEV1、FEV1/FVC均发生显著升高(P<0.05)。在常规治疗基础上采用胸腺肽α-1辅助治疗哮喘-慢阻肺重叠综合征能增强患者免疫力,改善肺功能,有效控制该病发作。

To investigate the therapeutic efficacy of thymosin alpha 1 on the asthma-COPD overlap syndrome,from October 2012 to October 2013,a total of 84 patients with asthma-COPD overlap syndrome in our hospital were divided into observation group（ n =44） and control group（ n = 40） according to whether it is subcutaneous injection of thymosin alpha 1. Observing the change of T lymphocyte subsets and pulmonary functions in the two groups pre and post treatment. Compared with the pre treatmenting in the observation group could be significantly enhanced the blood CD3＋,CD4＋,CD8＋and CD4＋/ CD8＋level（ P 〈 0. 05）. Compared with control group,observation group showed significant change of the blood CD3＋,CD4＋,CD8＋and CD4＋/ CD8＋level after treatment（ P 〈 0. 05）. Compared with the pre treatmenting,in the observation group could be significantly enhanced the FEV1 and FEV1 /FVC（ P 〈 0. 05）. Compared with control group,observation group showed significantly increased FEV1 and FEV1 /FVC after treatment（ P 〈 0. 05）. Thymosin alpha 1 in adjuvant therapy was applied in asthma-COPD overlap syndrome accompanied by routine treatment,enhancing immunity and improving pulmonary function.